United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 15,000 Shares

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 15,000 shares of the company’s stock in a transaction dated Friday, March 22nd. The shares were sold at an average price of $237.05, for a total transaction of $3,555,750.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $30,816.50. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

United Therapeutics Trading Down 1.9 %

NASDAQ:UTHR opened at $243.27 on Thursday. The stock’s 50 day moving average price is $225.55 and its 200 day moving average price is $227.39. United Therapeutics Co. has a 52 week low of $204.44 and a 52 week high of $261.54. The company has a market capitalization of $11.45 billion, a P/E ratio of 12.26 and a beta of 0.52. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.28 and a current ratio of 4.41.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The firm had revenue of $614.70 million for the quarter, compared to the consensus estimate of $575.01 million. During the same quarter in the prior year, the company posted $2.67 earnings per share. The firm’s revenue was up 25.1% on a year-over-year basis. On average, research analysts forecast that United Therapeutics Co. will post 23.32 EPS for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. grew its holdings in United Therapeutics by 6.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,636 shares of the biotechnology company’s stock valued at $580,000 after purchasing an additional 164 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its holdings in United Therapeutics by 540.5% during the fourth quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 23,700 shares of the biotechnology company’s stock valued at $5,211,000 after purchasing an additional 20,000 shares during the last quarter. Fisher Asset Management LLC grew its holdings in United Therapeutics by 5.8% during the fourth quarter. Fisher Asset Management LLC now owns 3,828 shares of the biotechnology company’s stock valued at $842,000 after purchasing an additional 209 shares during the last quarter. Virtu Financial LLC acquired a new position in United Therapeutics during the fourth quarter valued at approximately $1,353,000. Finally, Price T Rowe Associates Inc. MD grew its holdings in United Therapeutics by 31.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 32,045 shares of the biotechnology company’s stock valued at $7,048,000 after purchasing an additional 7,704 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. The Goldman Sachs Group raised shares of United Therapeutics from a “sell” rating to a “neutral” rating and upped their price target for the company from $213.00 to $215.00 in a report on Monday, February 12th. Wells Fargo & Company upped their price objective on shares of United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a research note on Thursday, March 7th. SVB Leerink assumed coverage on shares of United Therapeutics in a research note on Monday, February 5th. They set an “outperform” rating and a $330.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. Finally, Leerink Partnrs reaffirmed an “outperform” rating on shares of United Therapeutics in a research note on Monday, February 5th. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $294.40.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.